Gland Pharma Limited
₹3,097.50+₹22.65 (+0.7%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹28,321 Cr
- P/E
- 24.5x
- EV / EBITDA
- 17.3x
- Revenue
- ₹4,116 Cr
- Net margin
- 25.0%
- ROCE
- 15.7%
Price chart
Technical chartScreen technicals →+61.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +6.7%
- 3M
- +23.2%
- 6M
- +76.9%
- 1Y
- +61.9%
- 5Y
- -15.7%
52-week range
Day change +₹22.65 (+0.7%) from ₹3,075 to ₹3,098 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in GLAND, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 32.0%
Concerns0
Rule-based from financial data. Not advice.
About the company
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules.
Read moreShow less
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
- Sector
- Healthcare
- Shares outstanding
- 16.5 Cr shares
- ISIN
- INE068V01023
- BSE code
- 543245
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹28,321 Cr
- P/E
- 24.5x
- P/B
- 2.8x
- EV / EBITDA
- 17.3x
- EV / Sales
- 6.5x
- P/S
- 6.8x
- Earnings yield
- 4.1%
- 52-week high
- ₹3,151.95
- 52-week low
- ₹1,597.25
Profitability
- Operating margin
- 33.8%
- Net margin
- 25.0%
- EBITDA margin
- 37.8%
- ROE
- 11.6%
- ROCE
- 15.7%
- ROA
- 10.9%
- Dividend payout
- 32.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 11.8%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹4,116 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -1.2%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 9.6%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,576 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 31.0%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 4.5%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 6.2%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,136 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 208.7%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2,316 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.8%
Solvency and efficiency
- Current ratio
- 14.26
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- Debt / EBITDA
- 0.00
- Interest coverage
- 176.25
- Financial leverage
- 1.06
- CFO / Net profit
- 1.09
- Cash / Market cap
- 18.9%
- Cash per share
- ₹324.24
- Asset turnover
- 0.44
- Fixed asset turnover
- 2.46
- Capital intensity
- 0.41
- Debtor days
- 103 days
- Inventory turnover
- 1.44
- Cash conversion cycle
- 299 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹26 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹2,673 Cr |
| Sales | Operating profit | ₹1,443 Cr |
| Operating profit | Interest | ₹23 Cr |
| Operating profit | Depreciation | ₹169 Cr |
| Operating profit | Profit before tax | ₹1,251 Cr |
| Other income | Profit before tax | ₹215 Cr |
| Profit before tax | Tax and other | ₹376 Cr |
| Profit before tax | Net profit | ₹1,090 Cr |
Revenue and net profit
Revenue fell 1.2% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹3,463 Cr | ₹997 Cr |
| FY2022 | ₹4,401 Cr | ₹1,212 Cr |
| FY2023 | ₹3,617 Cr | ₹776 Cr |
| FY2024 | ₹4,167 Cr | ₹1,043 Cr |
| FY2025 | ₹4,116 Cr | ₹1,090 Cr |
Cash flows
FY2025: ₹1,074 Cr from operations, ₹2,656 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹605 Cr | -₹916 Cr |
| FY2022 | ₹791 Cr | -₹216 Cr |
| FY2023 | ₹368 Cr | ₹1,579 Cr |
| FY2024 | ₹1,136 Cr | -₹1,782 Cr |
| FY2025 | ₹1,074 Cr | ₹2,656 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹4,116 Cr-1.2%1Y
- Net profit
- ₹1,090 Cr+4.5%1Y
- Cash from operations
- ₹1,074 Cr
- Free cash flow
- ₹2,656 Cr
- Revenue CAGR, 5Y
- 9.6%
- EBITDA CAGR, 5Y
- 7.6%
- Net profit CAGR, 5Y
- 6.2%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹4,116 Cr | ₹1,443 Cr | — | ₹1,090 Cr | ₹1,074 Cr | ₹2,656 Cr | 11.2% | -1.2% | +4.5% |
Monthly returns
Month-by-month returns of GLAND across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹10,422 Cr |
| Equity capital | ₹16 Cr |
| Reserves | ₹9,739 Cr |
| Borrowings | ₹5 Cr |
| Other liabilities | ₹661 Cr |
| Assets | ₹10,422 Cr |
| Fixed assets | ₹1,745 Cr |
| Capital work in progress | ₹42 Cr |
| Investments | ₹2,790 Cr |
| Other assets | ₹5,845 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
GLAND trades at 24.5x earnings against a peer median of 52.6x (a 53% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Gland Pharma LimitedGLANDthis companyP/E ↓ discount | ₹28,321 Cr | 24.5x | 2.8x | 11.6% | 17.3x |
| Global Health LimitedMEDANTA | ₹31,404 Cr | 59.8x | 8.3x | 16.0% | 37.3x |
| Aster DM Healthcare LimitedASTERDM | ₹31,356 Cr | 92.8x | 7.1x | 5.4% | 78.2x |
| Emcure Pharmaceuticals LimitedEMCURE | ₹29,399 Cr | 67.9x | 9.1x | 8.3% | 53.5x |
| J.B. Chemicals & Pharmaceuticals LtJBCHEPHARM | ₹29,217 Cr | 41.5x | 7.9x | 18.8% | 32.1x |
| Syngene International LimitedSYNGENE | ₹25,375 Cr | 58.0x | 5.5x | 11.1% | 26.5x |
| Krishna Institute of Medical Sciences LimitedKIMS | ₹24,919 Cr | 87.7x | 10.9x | 12.6% | 65.6x |
| Pine Labs LimitedPINELABS | ₹24,711 Cr | 442.0x | — | -9.1% | 164.0x |
| Dr. Lal Pathlabs LimitedLALPATHLAB | ₹23,777 Cr | 45.0x | 10.2x | 20.2% | 38.3x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
GLAND since 1 January, against earlier years.
Historical volatility
GLAND's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 38.0% |
| FY2022 | 34.0% |
| FY2023 | 28.0% |
| FY2024 | 34.0% |
| FY2025 | 35.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹4,116 Cr |
| Costs | |
| Interest | ₹23 Cr |
| Expenses | ₹2,674 Cr |
| Operating profitOperating Profit | ₹1,443 Cr |
| Other income and charges | |
| Profit before tax | ₹1,466 Cr |
| Tax | |
| Net profitNet Profit | ₹1,090 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹10,422 Cr |
| Equity capitalEquity Capital | ₹16 Cr |
| Reserves | ₹9,739 Cr |
| Borrowings | ₹5 Cr |
| Other liabilitiesOther Liabilities | ₹661 Cr |
| AssetsTotal Assets | ₹10,422 Cr |
| Fixed assetsFixed Assets | ₹1,745 Cr |
| Capital work in progressCWIP | ₹42 Cr |
| Investments | ₹2,790 Cr |
| Other assetsOther Assets | ₹5,845 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹1,074 Cr |
| Investing cash flowCash from Investing Activity | ₹1,582 Cr |
| Financing cash flowCash from Financing Activity | -₹340 Cr |
| Change in cashNet Cash Flow | ₹2,316 Cr |
Learn while you research
Academy chapters picked for Gland Pharma Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read